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Hepatocellular carcinoma (HCC) is sexually dimor-
phic in both rodents and humans, with significantly
higher incidence inmales, an effect that is dependent
on sex hormones. The molecular mechanisms by
which estrogens prevent and androgens promote
liver cancer remain unclear. Here, we discover that
sexually dimorphic HCC is completely reversed in
Foxa1- and Foxa2-deficient mice after diethylnitros-
amine-induced hepatocarcinogenesis. Coregulation
of target genes by Foxa1/a2 and either the estrogen
receptor (ERa) or the androgen receptor (AR) was
increased during hepatocarcinogenesis in normal
female or male mice, respectively, but was lost in
Foxa1/2-deficient mice. Thus, both estrogen-depen-
dent resistance to and androgen-mediated facilita-
tion of HCC depend on Foxa1/2. Strikingly, single
nucleotide polymorphisms at FOXA2 binding sites
reduce binding of both FOXA2 and ERa to their
targets in human liver and correlate with HCC devel-
opment in women. Thus, Foxa factors and their
targets are central for the sexual dimorphism of HCC.
INTRODUCTION
Sexual dimorphism is the biological inequality between females
and males, favoring females in a variety of conditions including
resistance to nutrient deprivation, prevention of premature
aging, and resistance to diseases such as vascular and heart
disease, brain disorders, and hepatocellular carcinoma (HCC)
(Genazzani et al., 2007; Kalra et al., 2008; Stice et al., 2009).
Sex hormones, i.e., estrogens in females and androgens in
males, are the drivers of sexual dimorphism.
HCC is the fifth most common cancer and ranks third in annual
mortality worldwide (Parkin et al., 2005). Women show signifi-
cantly lower incidence of HCC than men (Parkin et al., 2005).
Female rodents are also resistant to HCC compared to males
during chemically induced carcinogenesis (Kalra et al., 2008).
Male mice treated with estrogen develop fewer liver tumors
than control males, and ovariectomized females develop more
liver tumors than normal females during chemically induced
carcinogenesis (Naugler et al., 2007; Shimizu et al., 1998; Tsutsui72 Cell 148, 72–83, January 20, 2012 ª2012 Elsevier Inc.et al., 1992; Yamamoto et al., 1991). In addition, female mice
deficient for the estrogen receptor alpha (ERa) lose their resis-
tance to HCC (Naugler et al., 2007), while reduced incidence of
HCC was observed in male mice lacking the androgen receptor
(AR) (Ma et al., 2008; Wu et al., 2010). These data demonstrate
that both protective effects of estrogens and deleterious effects
of androgens contribute to the sexual dimorphism in HCC inci-
dence. However, the molecular mechanisms of how this is
achieved remain to be determined.
A recent report suggested that estrogens prevent HCC
through inhibition of IL-6 expression in Kupffer cells, the resident
macrophages in the liver, and that this in turn affects hepatocyte
proliferation (Naugler et al., 2007). However, follow-up studies
employing IL-6 antagonists or estrogen and its analogs to
prevent HCC indicate that other mechanisms must also be
involved in estrogen-mediated protection from liver cancer (Di
Maio et al., 2006; Kalra et al., 2008; Lawrence et al., 2007).
Comparatively little is known about the mechanism by which
androgen signaling promotes HCC in males, although a recent
study suggests that androgens enhance DNA damage and
oxidative stress during hepatocarcinogenesis (Ma et al., 2008).
The vertebrate forkhead box A (Foxa) gene family of transcrip-
tion factors consists of three members, Foxa1, Foxa2, and
Foxa3, which are encoded by individual genes in mammals
(Kaestner, 2010). Previous gene ablation studies of Foxa factors
in mice have shown that Foxa1 and Foxa2 redundantly regulate
liver development and metabolism, whereas the role of Foxa3 in
the liver is limited (Bochkis et al., 2008; Friedman and Kaestner,
2006; Kaestner, 2005; Kaestner et al., 1998, 1999; Lee et al.,
2005; Li et al., 2009; Shen et al., 2001; Sund et al., 2000). Though
no liver forms in mice when both Foxa1 and Foxa2 are ablated in
foregut endoderm following gastrulation (Lee et al., 2005), abla-
tion of both Foxa1 and Foxa2 after liver specification does not
affect hepatocyte development or proliferation (Li et al., 2009).
Genome-wide location analyses have revealed that FOXA1
and ERa or AR frequently bind to adjacent cis-regulatory
elements in their target genes in human breast or prostate cancer
cell lines, respectively, and that the recruitment of ERa or AR to
their targets depends on FOXA1 (Carroll et al., 2005; Gao et al.,
2003; Lupien et al., 2008; Yu et al., 2005). Hence, FOXA1 plays an
essential role in estrogen and androgen signaling in breast and
prostate epithelia.
We hypothesized that the effects of estrogens and androgens
on HCC development are dependent upon Foxa factors.
Using liver-specific gene ablation, we demonstrate that sexually
Control Foxa1/2 Mutant
Female
A B P < 0.001
40
60
80
w
ei
gh
t/L
iv
er
 
gh
t (
%
)
P < 0.05
0
20
Control Mutant Control Mutant
Female Male
Tu
m
or
 w
W
ei
g
Male
941
Gene Expression (>= 1.5-fold)
Female vs Male
1078
Control Control
D
C Foxa1loxP/loxP;Foxa2loxP/loxP;AlfpCre (mutant)
6,612 +DEN
2,019
ahpla4FNH91KC
Female
tumor
tumor
Male
Figure 1. Foxa1 and Foxa2 Protect Female
Mice from HCC and Promote HCC in Male
Mice
(A) Livers from Foxa1loxP/loxP;Foxa2loxP/loxP
(control) and Foxa1loxP/loxP;Foxa2loxP/loxP;AlfpCre
(mutant) mice 18 weeks after exposure to hepatic
carcinogens.
(B) The percentage of tumor weight to liver weight
assayed by NMR. Five to six mice were analyzed in
each group.
(C) Immunostaining of cytokeratin 19 (CK19) and
hepatic nuclear factor 4 alpha (HNF4alpha) in livers
from Foxa1loxP/loxP;Foxa2loxP/loxP;AlfpCre mice.
Tumors are delimited by dotted lines. Arrows
indicate staining for CK19 (red) and HNF4alpha
(blue).
(D) Gender-differential gene expression in control
mice with or without carcinogen (DEN) adminis-
tration. Over 6,000 genes are expressed in gender-
specific fashion in control mice, but only 2,000
in mice exposed to carcinogen.
See also Figure S1.dimorphic HCC is dependent on Foxa1/2, and establish, using
genome-wide analyses, how the winged helix transcription
factors modulate the responses of the sex hormones in hepatic
carcinogenesis.
RESULTS
Foxa1/2 Protects Female Mice from HCC and Promotes
HCC in Male Mice
To investigate the role of Foxa factors in hepatocarcinogenesis,
we induced liver tumors in control and liver-specific Foxa1/2-
deficientmice (mutant) of both genders.We employed the estab-
lished N,N-diethylnitrosamine (DEN) followed by TCPOBOP
two-step strategy to induce rapid HCC formation in mice.
Consistent with previous reports (Kalra et al., 2008), male control
mice developed severe HCC following carcinogen treatment,
whereas female control mice were resistant to hepatocarcino-Cell 148, 72–8genesis, as evidenced by both direct
visualization and NMR quantification of
tumor nodules (Figures 1A and 1B). Strik-
ingly, multiple and large tumors were
found in female Foxa1/2-deficient livers
after carcinogen treatment, while tumor
growth in male mutants was reduced
when compared to controls (Figures 1A
and 1B). Thus, sexual dimorphic HCC
is dependent on the Foxa factors in
mice. Immunostaining for Cytokeratin 19
(CK19) and hepatic nuclear factor 4 alpha
(HNF4alpha), markers of cholangiocytes
and hepatocytes, respectively, confirmed
that the tumors in Foxa1/2-deficient livers
were HCC and not cholangiocarcinomas
(Figure 1C), consistent with the genotoxic
action of DEN on hepatocytes. In the two-
step strategy for hepatocarcinogenesis,phenobarbital-like inducers are commonly used for ‘‘boosting’’
tumor growth following tumor initiation by DEN (Oliver and
Roberts, 2002; Qatanani and Moore, 2005). These phenobar-
bital-like inducers are CAR (constitutive androstane receptor,
or Nr1i3) and PXR (pregnane X receptor, or Nr1i2) agonists. We
had included the phenobarbital-like inducer TCPOBOP in our
protocol, leading to the question of whether Foxa1/2-dependent
differential tumor growth was related to CAR/PXR signaling.
However, neither CAR nor PXR expression levels were corre-
lated with tumor load in our mice; in fact we saw the lowest levels
of CAR/PXR in female mutant mice treated with carcinogen,
which had the highest tumor load (Figure S1A available online).
Enhanced Coregulation of Target Genes by Foxa1/2 and
ERa in the Female Liver during Hepatocarcinogenesis
To investigate the mechanisms of relative HCC resistance in
female mice, we characterized gender-specific gene expression3, January 20, 2012 ª2012 Elsevier Inc. 73
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Figure 2. Enhanced Coregulation of Foxa and ERa/AR during Hepatocarcinogenesis
Livers from Foxa1loxP/loxP;Foxa2loxP/loxP (control) and Foxa1loxP/loxP;Foxa2loxP/loxP;AlfpCre (mutant) mice with/without carcinogen exposure for 18 weeks were
processed for ChIP-Seq analysis.
(A and B) Genome-wide coregulation by Foxa1/2 and ERa (A) or AR (B) in control liver with or without carcinogen treatment. Genes associated with Foxa1/2, ERa,
or AR were identified by ChIP-Seq analyses.
(C) Foxa/ERa dual-target genes potentially involved in resistance to hepatocellular carcinoma (HCC) in the liver of female mice before and after carcinogen
administration, defined as inborn and reactive protection, respectively.
See also Figure S2, Table S1, and Table S2.in mice with or without carcinogen treatment using microarray
analysis. 6,612 genes exhibited gender-specific differential
expression in control mice without carcinogen treatment (Fig-
ure 1D). Interestingly, only 2,019 genes were differentially ex-
pressed between female and male control mice after carcinogen
treatment, among which 1,078 genes were expressed in
a gender-specific fashion only after DEN treatment (Figure 1D).
This latter group is comprised of the gender-specific and carcin-
ogen-responsive genes, which may play a role in the resistance
to carcinogenesis in female mice and/or the promotion of carci-
nogenesis in male mice.
To identify Foxa and ERa target genes in the liver, we deter-
mined genome-wide binding sites of Foxa1, Foxa2, and ERa in
control female livers without carcinogen treatment by ChIP-
Seq. We also analyzed target genes associated with these
binding sites (Table S1). By intersecting these target genes
with the 6,612 genes showing gender-specific expression iden-
tified above (Figure 1D), we found 52% and 54% (919 and 1,117
genes) of ERa-associated genes associated with Foxa1 and
Foxa2 binding sites, respectively (Figure 2A), suggesting coregu-
lation of Foxa1/2 and ERa of the majority of genes modulating
gender dimorphism in females.
Next, we asked whether regulation of gender-dimorphic gene
expression was also dependent on the Foxa factors and ERa in74 Cell 148, 72–83, January 20, 2012 ª2012 Elsevier Inc.livers of female mice exposed to carcinogen. As shown above,
over 2,000 genes are expressed in a gender-specific fashion in
the liver of mice exposed to DEN (Figure 1D). When we analyzed
transcription factor binding in livers of female mice exposed to
carcinogen (Table S1), we found co-occupancy of the Foxa
factors with ERa greatly increased compared to the situation in
livers of untreated females, with 77%and 92%of the ERa-bound
genes also being targets of Foxa1 and Foxa2, respectively (Fig-
ure 2A), indicating enhanced coregulation of Foxa1/2 and ERa in
females during carcinogenesis. This finding suggests that the
protection of females from hepatocarcinogenesis might result
from coregulation of protective target genes by both Foxa1/2
and ERa. Further analysis revealed that the Foxa/ERa dual target
genes were almost equally distributed between those that were
expressed in gender-specific fashion before and after carcin-
ogen-treatment, which we define as ‘‘inborn protection’’ and
‘‘reactive protection,’’ respectively (Figure 2C).
Resistance to HCC in Females by Estrogen Signaling
Depends on Foxa1/2
Next, we analyzed genome-wide colocalization of Foxa1/2 and
ERa binding sites by calculating the distribution of ERa binding
sites relative to the center of the Foxa1 or Foxa2 binding sites.
Foxa1/2 and ERa binding sites were close to each other at the
Figure 3. Both Estrogen Signaling Preventing HCC and Androgen Signaling Promoting HCC Depend on Foxa1/2
Livers from Foxa1loxP/loxP;Foxa2loxP/loxP (control) and Foxa1loxP/loxP;Foxa2loxP/loxP;AlfpCre (mutant) mice with/without carcinogen (DEN) treatment for 18 weeks
were processed for ChIP-Seq analysis.
(A and D) Genome-wide distribution of ERa and AR binding sites relative to the center of Foxa1 or Foxa2 binding sites, respectively.
(B and E) Examples of Foxa1/2 and ERa or AR co-occupancy in an intron of the leukemia inhibitory factor receptor (Lifr) gene.
(C and F) The interactions between ERa/AR and Foxa1/2 were analyzed in liver homogenates by immunoprecipitation (IP) followed by western blotting (WB),
which were abolished in mutant liver.
See also Figure S3.regulatory regions of dual target genes in control females
(Figures 3A and 3B), suggesting coregulation and/or cooperative
binding by Foxa1/2 and ERa. Remarkably, Foxa1/2 and ERa
co-occupancy dramatically increased following carcinogen
treatment in female livers, paralleling the increased number of
binding sites of Foxa1, Foxa2, and ERa (Table S1 and Figures
3A and 3B), further supporting the notion that enhanced coregu-
lation of Foxa1/2 and ERa in response to carcinogen exposure
plays a critical role in protecting female mice from HCC. More
importantly, when we analyzed binding sites of ERa genome-
wide in Foxa1/a2 mutant livers, we found ERa binding dramati-
cally reduced (Table S1 and Figures 3A and 3B), providing
genetic evidence that the recruitment of ERa to its binding sites
depends to a very large extent on Foxa1/2.
FOXA1 has been found to directly interact with ERa in human
breast cancer cell lines (Carroll et al., 2005; Gao et al., 2003).
To investigate the mechanism by which Foxa1/2 and ERa
modulated tumor progression in the liver, we employed immuno-
precipitation with anti-Foxa1, anti-Foxa2, or anti-ERa antibodies
followed by western blot analysis. We found that both Foxa1
and Foxa2 are complexed with ERa in the female mouse liver
with or without carcinogen administration (Figure 3C), further
supporting the notion of coregulation of target genes by
Foxa1/2 and ERa. As expected, the interaction between
Foxa1/2 and ERa was abolished in Foxa1/2 mutant livers,
confirming the specificity of the immunoprecipitation assay
(Figure 3C).
Genomic distribution analysis showed that Foxa1, Foxa2,
and ERa binding sites were widespread in the genome, with
preference at enhancer regions (intergenic and intron regions)(Table S1 and Table S2). In addition, the common targets of
Foxa1/ERa were largely overlapping with those of Foxa2/ERa
in the female liver (Figure 4A). In total, we found 609 Foxa/ERa
common targets in genes for which gene expression changes
in response to carcinogen exposure (Figure 4A).
Next, we analyzed the gene expression profile of these 609
Foxa/ERa dual target genes in female control and Foxa1/a2
mutant liver following exposure to carcinogen. Strikingly, we
found that the change in gene expression for these Foxa/ERa
dual targets following DEN treatment was largely (for 77% of
the genes in question) reversed between control and mutant
female mice (Figure 4B). Thus, deficiency of Foxa1/2 caused
differential expression of Foxa/ERa dual targets, indicating that
the coregulation of Foxa/ERa dual target genes depends on
Foxa1/2.
To investigate the mechanism that caused enhanced coregu-
lation of Foxa and ERa, we analyzed the target occupancy of
each factor (Foxa1, Foxa2, or ERa) before and after carcinogen
treatment. We observed enhanced occupancy of Foxa1,
Foxa2, and ERa in livers of female mice exposed to carcinogen
(Figure S2A). To confirm this observation, we performed sequen-
tial ChIP-qPCR assays with anti-Foxa2 and anti-ERa antibodies
for 20 Foxa2/ERa targets identified by ChIP-Seq analysis. 16
targets were confirmed for both Foxa2 and ERa with at least
2-fold enrichment in liver of female control mice not treated
with carcinogen (Figure S3A). As expected, none of these genes
were ERa-bound in male mice, although 13 of them were bound
by Foxa2 (Figure S3C). All 20 targets showed significant binding
for both Foxa2 and ERa in livers of female mice after carcinogen
administration (Figure S3A). Linear regression analysis showedCell 148, 72–83, January 20, 2012 ª2012 Elsevier Inc. 75
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Figure 4. Comprehensive Protection from Hepato-
carcinogenesis by Foxa1/2 and ERa
Livers were collected from Foxa1loxP/loxP;Foxa2loxP/loxP
(control) and Foxa1loxP/loxP;Foxa2loxP/loxP;AlfpCre (mutant)
mice with/without carcinogen (DEN) treatment for
18 weeks.
(A and D) Foxa/ERa (A) or Foxa/AR (D) dual targets
potentially responsive to liver cancer resistance or
promotion in female or male mice, respectively.
(B and E) The change of gene expression of Foxa/ERa (B)
or Foxa/AR (E) dual targets in female or male control
mice was mostly reversed in mutant mice during hep-
atocarcinogenesis, respectively. DEN, mice with carcin-
ogen; NON, mice without carcinogen; MUT, mutant mice;
CTL, control mice.
(C and F) Pathway analysis of all Foxa/ERa (C) or Foxa/AR
(F) dual targets during hepatocarcinogenesis.
See also Figure S4 and Figure S7.that carcinogen exposure significantly enhanced binding of
Foxa2 and ERa to these common targets (Figure S3B). Interest-
ingly, enhanced Foxa2 binding at these loci was also observed in
male mice after carcinogen administration, although these sites
lacked ERa binding as expected (Figure S3C). Strikingly, we
found that ERa binding to all these targets was eliminated in
Foxa1/2-deficient livers, regardless of exposure to carcinogen
(Figure S3A), further demonstrating that ERa binding at these
dual targets is dependent on the presence of Foxa factors. Taken
together, these findings suggest that Foxa1/2 and ERa coop-
erate to regulate gene expression in the female liver, and that
Foxa1/2 is essential for estrogen signaling in the protection of
female mice from chemically induced hepatocarcinogenesis.
Comprehensive Protection from Hepatocarcinogenesis
by Foxa1/2 and ERa
Detailed analysis of the Foxa/ERa dual targets suggested that
these genes modulate multiple pathways in resistance to HCC,76 Cell 148, 72–83, January 20, 2012 ª2012 Elsevier Inc.as indicated by their gene annotations (Fig-
ure 4C). One of these targets is the oncogene
Myc. We found multiple Foxa2 and ERa binding
sites in Myc promoter and enhancer regions,
and confirmed Foxa2 and ERa co-occupancy
at these sites by sequential ChIP (Figure S4A).
In addition, we found that Myc expression
was significantly higher in female mutant
livers compared to controls after carcinogen
treatment (Figure S4B). When we suppressed
Myc expression in isolated hepatocytes from
DEN-treated Foxa1/2 mutant mice using
siRNA, hepatocyte proliferation was signifi-
cantly reduced as shown by Ki67 expression
(Figure S4C). These findings implicate Myc
as an important target for repression by
Foxa2/ERa in the livers of female mice.
However, as mentioned above, multiple genes
shown to be involved in cell-cycle control and
carcinogenesis are Foxa/ERa dual targets,
and multiple co-binding sites of Foxa1/2 andERawere also observed at regulatory regions of the ‘‘HCC-resis-
tant genes’’ as defined above. These genes are involved in
pathways related to cancer resistance, including xenobiotic
metabolism and detoxification, DNA biosynthesis and replica-
tion, and cell cycling and proliferation (Figure 4C and Figure S7).
Thus, Foxa1/2 and ERa coregulate multiple pathways of
hepatocarcinogenesis.
A prior study had proposed IL-6 as an essential mediator of
gender-specific hepatocarcinogenesis (Naugler et al., 2007).
We had found previously that gene ablation of Foxa1/2 after liver
specification led to mildly elevated IL-6 expression and bile duct
hyperplasia in the adult mouse liver (Li et al., 2009). Based on this
model, we expected that Foxa1/2-deficient livers would develop
more tumors than controls in both genders, because serum IL-6
levels were elevated similarly in male and female Foxa1/2mutant
mice (Figure S5). However, this was not the case, as female
Foxa1/2 mutant mice developed dramatically more and larger
tumors than male mutants (Figure 1A). Furthermore, while we
observed higher serum IL-6 levels in male mice compared to
female control mice after DEN administration, IL-6 levels in
DEN-treated mutant mice did not correlate with carcinogenesis
in males and females (Figure 1A and Figure S5). In addition,
the tumor load did not correlate with the levels of IL-6 among
all four groups (Figure 1A and Figure S5). Therefore, we conclude
that IL-6 is not a major factor regulating sexual dimorphism
of HCC.
Androgen Signaling Promoting HCC in Males Depends
on Foxa1/2
Remarkably, Foxa1/2 deficiency significantly reduced tumor
load in male mice after DEN administration (Figure 1A and 1B).
To investigate the molecular basis of this phenomenon, we
analyzed genome-wide binding sites and the corresponding
genes for Foxa1, Foxa2, and AR in control male livers without
carcinogen treatment by ChIP-Seq (Table S1). Genomic distribu-
tion analysis showed that Foxa1, Foxa2, and AR binding sites
were widespread in the genome, with preference at enhancer
regions (intergenic and intronic regions) (Table S1). The numbers
and occupancy of Foxa1, Foxa2, and AR binding sites were
greatly increased in livers of male mice exposed to carcinogen
as compared to controls (Table S1 and Figure S2B). Next, we in-
tersected Foxa1/2 and AR targets with the 6,612 genes showing
gender-specific expression in control mice without carcinogen
treatment (see Figure 1D). Among the intersect group, 75% or
72% (747 or 727 genes) of AR-associated genes were also
bound by Foxa1 or Foxa2, respectively (Figure 2B), indicating
potential coregulation of Foxa1/2 and AR in controlling gender
dimorphic gene expression in the male liver. We also analyzed
genome-wide binding sites of Foxa1, Foxa2, and AR in livers of
male mice exposed to DEN by ChIP-Seq (Table S1). Among
the genes (2,019) differentially expressed in the livers of male
and female mice following carcinogen treatment, Foxa1/2 and
AR target co-occupancy was even higher than among the
control group, with 86% and 86% of the AR-bound genes also
being targets of Foxa1 and Foxa2, respectively (Figure 2B).
Next, we analyzed genome-wide colocalization of Foxa1/2
and AR binding sites from ChIP-Seq by calculating the distribu-
tion of AR binding sites relative to the center of the Foxa1 or
Foxa2 binding sites. Foxa1/2 and AR binding sites were very
close to each other at the regulatory regions of their common
target genes (Figures 3D and 3E). Remarkably, Foxa1/2 and
AR co-occupancy dramatically increased following carcinogen
treatment in male livers (Figures 3D and 3E), further supporting
the notion that enhanced coregulation of Foxa1/2 and AR plays
a critical role in promoting HCC inmalemice. Strikingly, when we
analyzed target binding by AR in Foxa1/2mutant livers, we found
AR binding to the common Foxa/AR targets almost completely
abolished (Table S1 and Figures 2D and 2E), demonstrating
that the recruitment of AR to its binding sites depends on
Foxa1/2.
Both FOXA1 and FOXA2 have been found to directly interact
with the AR in human prostate cancer cells (Gao et al., 2003;
Yu et al., 2005). By immunoprecipitation assays, we found that
both Foxa1 and Foxa2were bound to AR in themalemouse liver,
regardless of exposure to DEN (Figure 3F). As expected, the
interaction between Foxa1/2 and AR was completely abolishedin Foxa1/a2mutant livers, confirming the specificity of our immu-
noprecipitation assay (Figure 3F).
In addition, the common Foxa1/AR targets were largely over-
lapping with those of Foxa2/AR in the male liver and were mostly
found at putative enhancer regions (Figure 4D and Table S2).
Just as was the case for the Foxa/ERa common targets, we
found that the difference in gene expression of Foxa/AR dual
targets between DEN-treated and -untreated control mice was
reversed for most (80%) genes in the livers of male Foxa1/a2
mutant mice (Figure 4E). Functional annotation of Foxa/AR
dual target genes revealed that Foxa1/2 and AR promote tumor
growth through multiple pathways, including DNA replication,
cell cycle, and cell growth and proliferation (Figure 4F). Taken
together, these findings demonstrate that Foxa1/2 and AR coop-
erate to regulate gene expression in the male liver, and that
Foxa1/2 are essential for androgen signaling in promoting hepa-
tocarcinogenesis in male mice.
Protective and Deleterious Effects of Estrogen
Hepatocyte injury is considered the first step in hepatocarcino-
genesis induced by DEN. Administration of estrogen to male
mice treated with DEN prevents liver injury and carcinogenesis
(Kalra et al., 2008), which we confirmed in our own study
(Figure 5A). In addition, administration of the ERa-specific
antagonist, fulverstrant (also called Faslodex), to female control
mice led to loss of protection from DEN-mediated liver injury,
confirming the importance of estrogen signaling in preventing
HCC (Figure 5A). However, we found that estrogen enhanced
liver injury in DEN-treated Foxa1/2-deficient male mice
(Figure 5A).
The data on tumor load in Foxa1/2 mutant mice present a new
puzzle (Figures 1A and 1B). If estrogen had only hepatoprotec-
tive effects, one would expect female Foxa1/2 mutant mice to
develop the same tumor load as male controls after exposure
to DEN. However, as shown above, the tumor load in female
mutants far exceeded that of male control mice (Figures 1A
and 1B). This suggests that in the absence of Foxa1/2, estrogens
exert an additional tumor-promoting effect on hepatocytes.
Estrogen itself has been found to act as a carcinogen due to
the genotoxicity of its metabolites, such as 16 alpha-hydroxy
estrone and 2- and 4-hydroxycatechol estrogens (Yager and
Liehr, 1996). When we blocked estrogen signaling with fulver-
strant, DEN-induced liver injury was significantly attenuated in
female Foxa1/2 mutant mice (Figure 5A). However, this tumor-
promoting effect of estrogen was only observed when Foxa1/2
was absent, indicating that the protective effect of estrogens is
normally dominant over its tumor-promoting action. Estrogens
have been employed clinically to treat many cancers with mixed
results: in some cases, estrogens were found to prevent cancer
progression; whereas in other cases, estrogens were found to
promote tumor growth (Di Maio et al., 2006; Kalra et al., 2008;
Lawrence et al., 2007). Our findings regarding the role of
Foxa1/2 in estrogen carcinogenesis provide a possible explana-
tion for these findings, in that estrogens prevent cancer progres-
sion in the liver when Foxa1/2 are present, but promote tumor
growth in the absence of the Foxa factors.
In addition to the Foxa/ERa dual targets discussed above,
there are alsomany genes solely bound by ERa in the female liverCell 148, 72–83, January 20, 2012 ª2012 Elsevier Inc. 77
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Figure 5. Protective and Deleterious Effects
of Estrogen
(A) Liver injury as indicated by alanine amino-
transferase (ALT) plasma levels in mice following
DEN administration. Male mice were treated
with 100 mg/kg estrogen (E2) and female mice
were treated with 50 mg/kg fulverstrant, a specific
inhibitor of ERa. *p < 0.05 from comparison
between female mutants with and without fulver-
strant, between female controls with and without
fulverstrant, and between male mutants with and
without E2.
(B) ERa-unique target genes show opposite
effects on female and male mutant mice after
carcinogen treatment.
(C) Functional pathway analysis of ERa-unique
targets during hepatocarcinogenesis.
See also Figure S5.(Table S1). These are candidate genes to explain the cancer-
promoting effects of estrogens in female mice lacking Foxa1/2.
Interestingly, many of these ERa-unique target genes showed
altered gene expression after carcinogen treatment, but with
changes in gene expression that were in the opposite direction
between female and male mutant mice (Figure 5B). Pathway
analysis revealed that most of these genes are involved in cell
cycle, cancer development, and nucleotide/amino acid metabo-
lism (Figure 5C). Thus, estrogen and its metabolites enhance
hepatocarcinogenesis through both their genotoxicity and tran-
scriptional regulatory activity when Foxa1 and Foxa2 are absent.
Foxa1/2-Guided Genomic Landscapes for Sex Hormone
Gene Regulation
The studies described above have shown gender-specific
recruitment of ERa and AR to Foxa1/2 binding sites in female
and male liver, respectively. In addition, we did not observe
significant differences of either Foxa1 or Foxa2 binding between
males and females, or of their core consensus sequences
(Figures S2C and S2D). Next, we compared the genomic loca-
tions of the 609 Foxa/ERa dual target genes that are likely
mediators of carcinogenesis resistance in females with the 726
Foxa/AR dual target genes that are likely promoting carcinogen-
esis in male mice. Strikingly, we found that the vast majority of
the targets (76% of Foxa/ERa and 64% of Foxa/AR) were over-
lapping between females and males (Figure 6A). For example,
leukemia inhibitory factor receptor (Lifr) was bound by Foxa/
ERa or Foxa/AR at the same location in female or male liver,
respectively (Figures 3B and 3E). De novo motif analysis showed
the presence of a strong consensus Foxa motif at these sites, as
expected (Figure 6B). Next, we searched for estrogen response
elements (ERE) and androgen response elements (ARE) in
proximity (±250 bp) to these Foxa binding sites. We found that78 Cell 148, 72–83, January 20, 2012 ª2012 Elsevier Inc.the distribution of ERE/ARE pairs was
random near these Foxa binding sites,
with half of the ERE/ARE pairs clustered
on either side of the Foxa core element,
and the other half separated by the Foxa
motif (Figure 6B). These data suggestthat adjacent localization of Foxa binding sites with both steroid
hormone receptor binding elements (ERE and ARE) enables
gender-specific regulation of the same set of genes by each
hormone in the liver.
A Role of FOXA1/2 in Human HCC
Mutations in gene coding regions are the predominant cause of
cancer. Where analyzed to date, hepatic FOXA1/2 levels did not
differ significantly in HCC patients compared to controls (Chen
et al., 2002; Lee et al., 2004, 2006), in concordance with our
results regarding Foxa1 and Foxa2 expression in mice treated
with DEN (Figure S1C) and previous reports in mice during
hepatocarcinogenesis (Kalra et al., 2008). However, our findings
suggest the possibility that mutations in cis-regulatory elements
binding FOXA1 and/or FOXA2 could predispose humans to
HCC. To investigate this possibility, we analyzed genome-wide
FOXA2 binding in healthy human livers by ChIP-Seq and found
7,917 FOXA2 binding sites. Next, we retrieved single nucleotide
polymorphisms (SNP) from the human GWAS database
(NCBI, build 130). By intersecting these two datasets, we found
12,739 SNPs, associated with 3,357 genes, located within 5,303
FOXA2 binding regions (Figure 7A). We intersected this human
gene list with the 609 dual Foxa/ERa targets (potential liver
cancer-resistance genes) identified above in the mouse liver
(Figure 4A). We obtained 228 potential ‘‘HCC-resistance genes’’
associated with 466 FOXA2 binding sites that contained 1,080
SNPs in the human orthologous loci (Figure 7A). Using the
MATCH program to search the binding elements of transcription
factors based on the positional weight matrices from the Trans-
fac database (Kel et al., 2003), we further identified FOXA2
consensus binding elements in these 466 FOXA2 ChIP-Seq
regions, and found that 119 of them contained SNPs within the
FOXA2 core binding element (TRTTT, R = G or A) (Figure 7A).
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Figure 6. Foxa-Guided Genomic Landscape for Sex Hormone Gene
Regulation
(A) Genes regulating both cancer resistance in females and cancer promotion
in males that are targeted by Foxa and ERa, Foxa and AR, or both.
(B) Genomic distribution of estrogen response elements (ERE) and androgen
response elements (ARE) near Foxa binding sites. Genomic regions near Foxa
binding elements (±250 bp) were used to search ERE and ARE. Two groups of
ERE-ARE pairs near Foxa2 binding elements at each locus were found: half
were separated by Foxa motifs (upper panel); the other half were paired on
either side of Foxa binding sites (bottom panel).In order to investigate the impact of FOXA2 SNPs on estrogen
signaling, we determined FOXA2 and ERa binding at regions
of ± 200 bp surrounding these FOXA2 core binding elements
by ChIP-qPCR in samples from four healthy and four HCC livers
from women. Among the 113 FOXA2 binding sites tested, 18
sites showed significant reduction in binding to both FOXA2
and ERa in some or all HCC livers compared to controls (Fig-
ure S6). To identify SNPs at these FOXA2 binding sites, we
sequenced these 18 loci in the HCC samples and found multiple
point mutations, deletions, and insertions that were either
heterozygous or homozygous (Figures S6 and Figure 7B). In
most cases, SNPs at FOXA2 binding sites were associated
with impaired FOXA2 and ERa binding (Figure S6). In particular,
the BTG1 (B cell translocation gene 1), FGL1 (fibrinogen-like 1),
and ABCC4 (ATP-binding cassette, subfamily C (CFTR/MRP),
member 4) loci had mutations at one or two alleles causing
loss of binding of both FOXA2 and ERa in all four HCC patients,
while three out of four HCC samples contained mutations in the
PPM1L (protein phosphatase, Mg2+/Mn2+ dependent, 1L) locus
(Figure S6B). All loci with mutations also showed impairedbinding of both FOXA2 and ERa (Figure S6B). BTG1 is an anti-
proliferative factor (Rouault et al., 1992), FGL1 is an acute phase
reactant for inflammatory response (Liu and Ukomadu, 2008),
ABCC4 mediates the membrane transport of various molecules
inmulti-drug resistance (Russel et al., 2008; Vlaming et al., 2006),
and PPM1L is a tumor suppressor (Thean et al., 2010). To
confirm this observation, we analyzed additional seven normal
and seven HCC livers from women. When analyzing all 22
samples, we found that both FOXA2 and ERa binding were
highly correlated with the sequence of the FOXA2 binding
elements (Figure S6C), and that FOXA2/ERa dual occupancy
was significantly different between normal and HCC livers (Fig-
ure 7C). Impaired binding of both FOXA2 and ERa occurred
predominantly in female HCC livers (Figure 7C), which we postu-
lated would lead to altered gene expression of BTG1, FGL1,
ABCC4 and PPM1L, which in turn might contribute to the devel-
opment of HCC. Indeed, when we performed immunostaining of
these four proteins for liver sections from female HCC patients
and normal controls, we found that PPM1L expression was
reduced and FGL1, BTG1 and ABCC4 expression was increased
in HCC livers compared to normal controls (Figure 7D). These
data suggest that impaired regulation by FOXA2 and ERa
contributed to altered expression of these dual target genes in
HCC and supports the notion that SNPs at FOXA2 binding sites
could contribute to HCC risk in women.
DISCUSSION
Hepatocellular carcinoma is an often lethal malignancy with
limited treatment options. Here, we have uncovered a central
role for the winged helix transcription factors Foxa1 and Foxa2
in controlling estrogen and androgen signaling through recruit-
ment of ERa and AR to their relevant targets in the liver, thereby
explaining the sexual dimorphism of liver cancer in mammals.
Not only are the Foxa factors required for the sex hormone
receptors to bind to many of their targets, importantly, tumor
growth is also strongly dependent on Foxa1/2. Thus, tumor
load is dramatically increased in the livers of female Foxa1/2
mutant mice, and decreased in the livers of male Foxa1/2
mutants exposed to hepatocarcinogens. Our current view of
how the Foxa1/2 factors control multiple aspects of hepatocar-
cinogenesis is summarized in the schema provided in Figure S7.
Prevention of liver cancer through ERa-dependent gene regula-
tion in female mice, and AR-mediated promotion of liver cancer
inmale mice depend on Foxa1/2. Binding of the steroid hormone
receptors to those of their targets that are near Foxa binding
sites is abolished in the absence of the Foxa factors. The genes
sets regulated jointly by the sex hormone receptors and Foxa
factors cluster in the pathways controlling xenobiotic metabo-
lism and carcinogen detoxification, DNA biosynthesis and repli-
cation, and cell cycle and proliferation.
The Foxa factors play a dominant role in determining the
gender specificity of HCC development. Interestingly, without
carcinogen treatment, Foxa1/2 mutant mice maintain much of
the sexual dimorphic gene expression profile that is present in
control livers (data not shown). This suggests that the loss of
gender specificity in Foxa1/2-deficient mice occurs with the
onset of carcinogen exposure. Given the fact that multipleCell 148, 72–83, January 20, 2012 ª2012 Elsevier Inc. 79
Figure 7. The Relationship between Hepatocellular Carcinoma and Single Nucleotide Polymorphisms at FOXA2 Binding Sites in Women
(A) Computational procedure for identifying SNPs at FOXA2 binding sites. Human SNPs were downloaded from the NCBI GWAS database (Build 130). FOXA2
binding sites in normal human livers were identified by FOXA2 ChIP-Seq. Potential HCC-resistance genes were identified from our mouse models described
(Figure 1D).
(B) Examples of sequencing results for SNPs at FOXA2 binding sites associated with BTG1. The asterisk indicates the nucleotide with SNP from T to C.
(C) Synergic reductions of FOXA2 and ERa binding at FOXA2 binding sites containing SNPs are associated with increased incidence of HCC. FOXA2 binding
regions with potential SNPs were sequenced in 11 healthy (normal) and 11HCC livers fromwomen. ChIP assays with anti-FOXA2 or anti-ERa antibodies revealed
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physiological and pathophysiological processes are sexually
dimorphic in the organs expressing Foxa proteins, we speculate
that other stresses, like dietary deprivation and aging, might also
invoke gender-specific responses from Foxa factors, which we
aim to address in the future.
A previous study had attributed the disparity in liver cancer
between the sexes to differences in IL-6 production by Kupffer
cells in response to chemical carcinogens (Naugler et al.,
2007). In fact, DEN-induced tumor incidence was reduced in
both male and female IL-6 null mice. However, while we
confirmed higher IL-6 plasma levels in wild-type male mice
treated with DEN compared to female controls, IL-6 levels did
not correlate with tumor load in Foxa1/2-deficient mice (Fig-
ure 1A and Figure S5). In addition, because Foxa1/2 were not
ablated in Kupffer cells but in hepatocytes in our model, the
effect of the sex hormones on tumor susceptibility shown here
is exclusively due to direct action of the Foxa factors on the
parenchymal cells in the liver.
Estrogen promotes and estrogen antagonists (such as tamox-
ifen) prevent the growth of breast cancer cells, at least in
estrogen receptor-positive tumors (Hollingsworth et al., 1998;
Zumoff, 1998). Androgen promotes and androgen deprivation
prevents the growth of prostate cancer cells (Paulson, 1984;
Smolev et al., 1977). As discussed above, in both cancers,
binding of the sex hormone receptor occurs near FOXA binding
sites. However, in liver cancer, a different scenario has been
recognized for years, in that estrogen prevents cancer develop-
ment, opposite to the situation in the mammary gland. As we
have shown here, both the effects of androgens and estrogens
are Foxa1/2-dependent in the liver. Thus, a puzzle emerges:
how can it be that estrogen signaling, dependent on Foxa factors
in both the mammary gland and the liver, is tumor-promoting in
the former, and tumor-preventing in the latter? This paradox
suggests the existence of tissue-specific targets or tissue-
specific coregulation of the Foxa/ERa axis in the two tissues,
an issue that will be of great interest for future investigation.
Thus far, no mutations in the FOXA1 or FOXA2 gene have
been linked to human HCC. This might not be too surprising
given the redundant function of the two proteins, which
suggests that mutations in one or the other might not be
sufficient to affect tumor initiation or progression. However,
strikingly, we found multiple examples of single nucleotide poly-
morphisms in FOXA binding sites that affect FOXA and ERa
occupancy, which were significantly more frequent in HCC
samples than in normal livers from women. Not only does this
finding provide supporting evidence that the coregulation of
target genes by FOXA and ERa extends from mice to humans,
but it also suggests that SNPs in FOXA binding sites could
contribute to the risk of hepatocarcinogenesis in women. Futurethat mutations at core FOXA2 binding sites were associated with impaired binding
occupancy of both FOXA2 and ERa (ChIP enrichment) in all samples was highly c
Homo, homozygous SNPs. These mutations were found at FOXA2 binding s
dependent, 1L), FGL1 (fibrinogen-like 1), BTG1 (B cell translocation gene 1), and
occupancy of FOXA2 and ERa is significantly reduced in HCC livers compared to
and ERa between 11 normal and 11 HCC livers by t test.
(D) Immunohistochemical detection of PPM1L, FGL1, BTG1, and ABCC4 in the l
See also Figure S6.large-scale studies investigating HCC risk in women with
respect to these SNPs appear warranted.
We previously found that glucocorticoid receptor (GR)-medi-
ated transcriptional regulation also depends on Foxa1/2 (Li
et al., 2009; Zhang et al., 2005). Full activation of certain genes
in the liver in response to a prolonged fast, and engagement of
their cis-regulatory elements by GR requires Foxa2 (Zhang
et al., 2005). Likewise, repression of the IL-6 promoter by GR is
dependent on the Foxa factors in hepatocytes (Li et al., 2009).
Why are Foxa factors required for steroid hormone signaling?
Our current study suggests that Foxa factors serve as a scaffold
for steroid hormone receptors to regulate gene transcription in
the liver on a genome-wide scale, and extends to at least three
nuclear hormone receptors. Our finding that two sets of sex
hormone cis-regulatory elements, AREs and EREs, are found
close to the same Foxa binding site suggests that Foxa-depen-
dent estrogen and androgen signaling regulates the same set of
genes in the liver (Figure S7). More importantly, our studies
showed that ERa and AR had opposite effects on this gene set
between females and males (Figure 4 and Figure S7), which
provides a molecular explanation for previous findings that
estrogen and androgen were able to reverse HCC incidence in
the opposite genders (Naugler et al., 2007; Shimizu et al.,
1998; Tsutsui et al., 1992; Yamamoto et al., 1991). In conclusion,
we have identified a set of regulatory units in which juxtaposition
of Foxa binding sites next to both EREs and AREs allows for the
mediation of the gender-specific effects of the sex hormones in
the liver.
EXPERIMENTAL PROCEDURES
Mice and Hepatocarcinogenesis
Foxa1loxP/loxP;Foxa2loxP/loxP (control) and Foxa1loxP/loxP;Foxa2loxP/loxP;AlfpCre
(mutant) mice were derived previously (Gao et al., 2008; May et al., 2009;
Sund et al., 2000). A two-step strategy was used for hepatocarcinogenesis.
Briefly, 14-15 day old mice were injected with DEN (20 mg/kg body weight)
(Sigma) to initiate tumor growth. Beginning at 28 days, mice were injected
with TCPOBOP (3mg/kg bodyweight) (Sigma) once every twoweeks for a total
of eight times to promote tumor growth. DEN-induced liver injury experiments
were carried out as described previously (Naugler et al., 2007), except that
50 mg/kg body weight Faslodex or estrogen were intraperitoneally injected
daily for seven days before DEN treatment. Serum IL-6 levels were measured
by ELISA (R&D Systems), and serum ALT activities by coupled enzymatic
reaction (Genzyme Diagnostics). All animal experiments were approved
by the Institutional Animal Care and Use Committee at the University of
Pennsylvania.
Chromatin Immunoprecipitation High-Throughput Sequencing
and ChIP Assays
ChIP was performed as described previously (Rubins et al., 2005). For ChIP-
Seq, chromatin was further sonicated to reduce size, and immunoprecipitated
with anti-Foxa1 (Santa Cruz, Abcam), anti-Foxa2 (a kind gift of J. Whitsett),of both FOXA2 and ERa, shown as ChIP enrichment in livers from women. The
orrelated with the number of mutation in both alleles. Hez, heterozygous SNP;
ites associated with four genes PPM1L (protein phosphatase, Mg2+/Mn2+
ABCC4 (ATP-binding cassette, subfamily C (CFTR/MRP), member 4). The co-
normal controls. p values are from the comparison of co-occupancy of FOXA2
ivers of normal and HCC women. Magnification X 200.
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anti-ERa (Santa Cruz, Invitrogen) or anti-AR antibodies (Santa Cruz, Fisher
Thermoscientific, Millipore). For ChIP assays, input and precipitated DNA
were subjected to quantitative real-time PCR (qPCR). Enrichment of the
targets was calculated using the 28S rRNA loci as reference, and is shown
relative to the input. For ChIP-Seq data, peaks were called using GLITR and
HOMER (Heinz et al., 2010; Tuteja et al., 2009). De novo motif analysis for
Foxa2, ERE, and AREwas performed with HOMER based on positional weight
matrices from TRANSFAC (version 8.3). Once Foxa2 binding elements were
identified in 317 Foxa2 binding regions (Figure 6), nearby regions were
searched for EREs and AREs. ChIP-Seq data are available in Array Express
(E-MTAB-805).
Expression Profiling
Liver RNA was isolated from control and Foxa1/2 mutant mice at three months
of age with or without carcinogen administration for both genders (n = 4 per
group). Fluorescently labeled cDNAs were hybridized to the Whole Mouse
Genome Oligo Microarray (Agilent) (Gao et al., 2009). Genes displaying
a greater than 1.5-fold change between mutants and controls and a false
discovery rate (FDR) less than 10% by SAM analysis (Tusher et al., 2001)
were selected. Gene profiling data have been deposited to GEO (GEO
GSE32244). Gene ontologies were analyzed with the NIH DAVID tool and func-
tional pathways of relevant genes were analyzed with the Ingenuity program.
Immunoprecipitation
Liver homogenates were obtained from a piece of liver without visible tumors in
RIPA buffer with protease inhibitors cocktails (Roche). 2.5 mg liver protein was
used for each assay. Protein G-conjugated Dynal magnetic beads (Invitrogen)
were employed to purify the protein complexes bound by anti-ERa, anti-AR,
anti-Foxa1, or anti-Foxa2 antibodies.
Human Liver Samples
Frozen liver samples of four healthy women and four women with primary HCC
were obtained from the Penn Morphology Core (NIDDK P30DK050306).
ChIP-qPCR was carried out as described above for FOXA2 and ERa. The
MATCH program (Kel et al., 2003) with a core score of 1.0 and thematrix score
of > 0.9 was used to search for the FOXA2 binding site in ChIP-Seq regions.
Genomic DNA was extracted from these liver samples with the QIAGEN
DNeasy kit and sequenced. Immunohistochemical staining was performed
with anti-PPM1L, anti-FGL1, anti-BTG1, and anti-ABCC4 antibodies (Sigma,
HPA019953, F6806, HPA005972, and SAB2500011).
Suppression of Gene Expression by RNAi
Myc siRNA was purchased from Integrated DNA Technology (IDT). Primary
hepatocytes were isolated from female DEN-treatedmutant mice and cultured
in DMEM with 17% FBS. RNAiMAX (Invitrogen) was used to transfect 10 nM
siRNA into 5X105 cells. Cells were collected at 48 hr after transfection for
mRNA analysis by qPCR.
ACCESSION NUMBERS
All ChIP-Seq data and analysis are deposited in the ArrayExpress database
with accession number E-MTAB-805. Gene profiling data (32 microarrays)
and analysis have been deposited to two files under accession number
E-MTAB-514 (8 microarrays) and GSE32244 (24 microarrays).
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